Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer

Author:

Beyer Susanne1ORCID,Wehrmann Maya1,Meister Sarah1,Trillsch Fabian1ORCID,Ganster Franziska1,Schmoeckel Elisa2,Corradini Stefanie3ORCID,Mahner Sven1,Jeschke Udo14ORCID,Kessler Mirjana1ORCID,Burges Alexander1,Kolben Thomas1ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany

2. Institute of Pathology, TUM School of Medicine and Health, Trogerstraße 18, 81675 Munich, Germany

3. Department of Radiation-Oncology, University Hospital, LMU Munich, 81377 Munich, Germany

4. Department of Obstetrics and Gynecology, University Hospital, Universitätsklinikum Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany

Abstract

Endometrial cancer (EC) is a common gynecological cancer worldwide. Treatment has been improved in recent years; however, in advanced stages, therapeutic options are still limited. The expression of galectins is increased in several tumor types and that they are involved in important cell processes. Large studies on endometrial cancer are still pending; Specimens of 225 patients with EC were immunohistochemically stained with antibodies for Gal-8 and Gal-9. Expression was correlated with histopathological variables. The cytosolic expression of both galectins is associated with grading and survival. Cytosolic Galectin-8 expression is a positive prognostic factor for overall survival (OS) and progression-free survival (PFS), while nuclear Gal-8 expression correlates only to OS. The cytosolic presence of Galectin-9 is correlated with a better prognosis regarding OS. Our results suggest that expression of both galectins is associated with OS and PFS in EC. Further studies are needed to understand the underlying molecular mechanisms.

Publisher

MDPI AG

Reference52 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Diagnosis and Management of Endometrial Cancer;Braun;Am. Fam. Physician,2016

3. American Cancer Society (2014, October 27). Cancer Facts and Figures. Available online: https://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.

4. Two pathogenetic types of endometrial carcinoma;Bokhman;Gynecol. Oncol.,1983

5. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series;Kommoss;Ann. Oncol.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3